Institutional shares held 133 Million
1.12M calls
1.83M puts
Total value of holdings $12.9B
$108M calls
$177M puts
Market Cap $208B
2,151,000,064 Shares Out.
Institutional ownership 6.2%
# of Institutions 1,438


Latest Institutional Activity in NVS

Top Purchases

Q3 2024
Dimensional Fund Advisors LP Shares Held: 8.09M ($784M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 3.49M ($338M)
Q3 2024
Arrowstreet Capital, Limited Partnership Shares Held: 900K ($87.1M)
Q3 2024
Fisher Asset Management, LLC Shares Held: 1.71M ($165M)
Q3 2024
Mediolanum International Funds LTD Shares Held: 208K ($20.1M)

Top Sells

Q3 2024
Franklin Resources Inc Shares Held: 4.38M ($424M)
Q3 2024
Cullen Capital Management, LLC Shares Held: 2.25M ($218M)
Q3 2024
Morgan Stanley Shares Held: 6.98M ($676M)
Q3 2024
Wellington Management Group LLP Shares Held: 4M ($387M)
Q3 2024
Northern Trust Corp Shares Held: 1.73M ($168M)

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.


Insider Transactions at NVS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on NVS

Follow NOVARTIS AG and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVS shares.

Notify only if

Insider Trading

Get notified when an Novartis Ag insider buys or sells NVS shares.

Notify only if

News

Receive news related to NOVARTIS AG

Track Activities on NVS